Updates are available Correction dated 2018-10-02
Click to view Correction: https://doi.org/10.1038/s41386-018-0118-5
-
Authors
Modinos, Gemma https://orcid.org/0000-0002-7870-066X
Şimşek, Fatma
Azis, Matilda
Bossong, Matthijs
Bonoldi, Ilaria
Samson, Carly
Quinn, Beverly
Perez, Jesus
Broome, Matthew R
Zelaya, Fernando
Lythgoe, David J
Howes, Oliver D
Stone, James M https://orcid.org/0000-0003-3051-0135
Grace, Anthony A https://orcid.org/0000-0003-1864-5504
Allen, Paul
McGuire, Philip
- License Information
-
More Information
Article History
Received: 28 August 2017
Revised: 20 December 2017
Accepted: 27 December 2017
First Online: 30 January 2018
Change Date: 2 October 2018
Change Type: Correction
Change Details: This article was originally published under NPG’s License to Publish, but has now been made available under a [CC BY 4.0] license. The PDF and HTML versions of the paper have been modified accordingly.
ADDITIONAL INFORMATION
:
: AAG receives consulting fees from Johnson & Johnson, Lundbeck, Pfizer, GSK, Merck, Takeda, Dainippon Sumitomo, Otsuka, Lilly, Roche, Asubio, and Abbott; and receives research funding from Lundbeck, Lilly, Autifony, Alkermes, and Johnson & Johnson. OH has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Astra-Zeneca, Autifony, BMS, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, Rand and Roche. Neither OH nor his family have been employed by or have holdings/a financial stake in any biomedical company. The remaining authors declare that they have no conflict of interest.
